Header Logo

Connection

JOSEPH KHOURY to Myelodysplastic Syndromes

Back to Details
This is a "connection" page, showing publications JOSEPH KHOURY has written about Myelodysplastic Syndromes.
JOSEPH KHOURY
Connection Strength
2.833
Myelodysplastic Syndromes
  1. Myelodysplastic neoplasms evolving from inherited bone marrow failure syndromes / germline predisposition syndromes: Back under the microscope. Leuk Res. 2024 02; 137:107441.
    View in: PubMed
    Score: 0.353
  2. Where diagnosis for myelodysplastic neoplasms (MDS) stands today and where it will go: The role of flow cytometry in evaluation of MDS. Cytometry B Clin Cytom. 2023 01; 104(1):12-14.
    View in: PubMed
    Score: 0.328
  3. Myelodysplastic Syndromes: Laboratory Workup in the Context of New Concepts and Classification Criteria. Curr Hematol Malig Rep. 2018 12; 13(6):467-476.
    View in: PubMed
    Score: 0.247
  4. Pure erythroid leukemia. Am J Hematol. 2017 03; 92(3):292-296.
    View in: PubMed
    Score: 0.218
  5. TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis. Br J Haematol. 2015 Oct; 171(1):91-9.
    View in: PubMed
    Score: 0.195
  6. Comprehensive analysis of factors impacting risks and outcomes of therapy-related myeloid neoplasms following breast cancer treatment. Leukemia. 2016 Jan; 30(1):242-7.
    View in: PubMed
    Score: 0.193
  7. Images in HIV/AIDS. HIV and myelodysplasia. AIDS Read. 2009 Apr; 19(4):156-7.
    View in: PubMed
    Score: 0.126
  8. Can molecular patterns help to classify overlapping entities in myeloid neoplasms? Histopathology. 2025 Jan; 86(1):146-157.
    View in: PubMed
    Score: 0.093
  9. Fifth Edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissue: Myeloid Neoplasms. Mod Pathol. 2024 Feb; 37(2):100397.
    View in: PubMed
    Score: 0.087
  10. Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies. Clin Cancer Res. 2023 11 01; 29(21):4352-4360.
    View in: PubMed
    Score: 0.087
  11. Clinicopathologic Features of Therapy-Related Myeloid Neoplasms in Patients with Myeloma in the Era of Novel Therapies. Mod Pathol. 2023 06; 36(6):100166.
    View in: PubMed
    Score: 0.083
  12. Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes. Mod Pathol. 2022 09; 35(9):1212-1219.
    View in: PubMed
    Score: 0.078
  13. Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients. Leukemia. 2022 05; 36(5):1343-1350.
    View in: PubMed
    Score: 0.078
  14. Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. Blood Cancer J. 2021 03 06; 11(3):52.
    View in: PubMed
    Score: 0.072
  15. Clinical Applications of Chromosomal Microarray Testing in Myeloid Malignancies. Curr Hematol Malig Rep. 2020 06; 15(3):194-202.
    View in: PubMed
    Score: 0.069
  16. Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. Am J Hematol. 2020 06; 95(6):612-622.
    View in: PubMed
    Score: 0.068
  17. A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure. Leuk Lymphoma. 2019 09; 60(9):2207-2213.
    View in: PubMed
    Score: 0.063
  18. Characterization of IDH1 p.R132H Mutant Clones Using Mutation-specific Antibody in Myeloid Neoplasms. Am J Surg Pathol. 2018 05; 42(5):569-577.
    View in: PubMed
    Score: 0.059
  19. Characteristics and clinical implications of reactive germinal centers in the bone marrow. Hum Pathol. 2017 10; 68:7-21.
    View in: PubMed
    Score: 0.055
  20. Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. Cancer. 2017 Feb 15; 123(4):629-637.
    View in: PubMed
    Score: 0.053
  21. Double minute chromosomes in acute myeloid leukemia, myelodysplastic syndromes, and chronic myelomonocytic leukemia are associated with micronuclei, MYC or MLL amplification, and complex karyotype. Cancer Genet. 2016 Jul-Aug; 209(7-8):313-20.
    View in: PubMed
    Score: 0.052
  22. Dyspoietic changes associated with hepatosplenic T-cell lymphoma are not a manifestation of a myelodysplastic syndrome: analysis of 25 patients. Hum Pathol. 2016 Apr; 50:109-17.
    View in: PubMed
    Score: 0.050
  23. Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation. Cancer Genet. 2015 Nov; 208(11):571-4.
    View in: PubMed
    Score: 0.049
  24. MLL gene amplification in acute myeloid leukemia and myelodysplastic syndromes is associated with characteristic clinicopathological findings and TP53 gene mutation. Hum Pathol. 2015 Jan; 46(1):65-73.
    View in: PubMed
    Score: 0.046
  25. Case Report of Myeloid Sarcoma Masquerading as In-Transit Metastasis at a Previous Melanoma Site: Avoiding a Diagnostic Pitfall. Am J Dermatopathol. 2018 Nov; 40(11):831-835.
    View in: PubMed
    Score: 0.015
  26. KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice. Blood Adv. 2018 10 09; 2(19):2491-2504.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.